Publikationen

2021

2021

  1. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH, Hirt C
    , Basara N, Sayer HG, Behre G, Fischer T, Grobe N, Maschmeyer G, Neumann T, Schneidewind L, Niederwieser D, Dölken GSchmidt CA.Ann Hematol. 2021 Apr 8. doi: 10.1007/s00277-021-04506-y. Online ahead of print.PMID: 33829299
  2. Unveiling the N-Terminal Homodimerization of BCL11B by Hybrid Solvent Replica-Exchange Simulations.
    Schulig L, Grabarczyk P, Geist N, Delin M, Forkel H, Kulke M, Delcea M, Schmidt CA, Link A.Int J Mol Sci. 2021 Mar 31;22(7):3650. doi: 10.3390/ijms22073650.PMID: 33807484 
  3. Implementation of Palliative Care in Clinical Practice in German Units for Allogeneic Stem Cell Transplantation: A Nationwide Survey.
    Krüger W, Buchhold B, Nonnenberg D, Neumann T, Schneidewind L, Schmidt CA.Am J Hosp Palliat Care. 2021 Jan 12:1049909120986963. doi: 10.1177/1049909120986963. Online ahead of print.PMID: 33433238
  4. Histone PTM Crosstalk Stimulates Dot1 Methyltransferase Activity.
    Cutler JA, Perner F, Armstrong SA.Trends Biochem Sci. 2021 Apr 17:S0968-0004(21)00067-0. doi: 10.1016/j.tibs.2021.04.001. Online ahead of print.PMID: 33879367
  5. Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study.
    Eichler M, Andreou D, Golcher H, Hentschel L, Richter S, Hohenberger P, Kasper B, Pink D, Jakob J, Ashmawy H, Hettmer S, Tuchscherer A, Grube M, Heidt V, Jentsch C, Pablik J, Wardelmann E, Kreitner KF, Kneser U, Tonus C, Wimberger P, Schoffer O, Reichardt P, Wartenberg M, Eberlein-Gonska M, Bornhäuser M, Schmitt J, Schuler MK.Oncol Res Treat. 2021 Apr 22:1-9. doi: 10.1159/000516262. Online ahead of print.PMID: 33887740
  6. Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06).
    Pink D
    , Andreou D, Bauer S, Brodowicz T, Kasper B, Reichardt P, Richter S, Lindner LH, Szkandera J, Grünwald V, Kebenko M, Kirchner M, Hohenberger P.Cancers (Basel). 2021 Mar 11;13(6):1223. doi: 10.3390/cancers13061223.PMID: 33799576 
  7. [Treatment of soft tissue sarcomas including GIST - Update 2021].
    Reichardt P, Pink D.Dtsch Med Wochenschr. 2021 Feb;146(3):157-161. doi: 10.1055/a-1170-7731. Epub 2021 Jan 29.PMID: 33513648
  8. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
    Al-Batran SE, Hofheinz RD, Reichart A, Pauligk C, Schönherr C, Schlag R, Siegler G, Dörfel S, Koenigsmann M, Zahn MO, Schubert J, Aldaoud A, Höffkes HG, Schulz H, Hahn L, Uhlig J, Blau W, Stauch M, Weniger J, Wolf M, Jacobasch L, Bildat S, Wehmeyer J, Homann N, Trojan J, Waidmann O, Fietz T, Feustel HP, Groschek M, Wierecky J, Waibel K, Mahlmann S, Schwindel U, Peters U, Schuch G, Pink D, Eschenburg H, Wörns MA, Harich HD, von Weikersthal LF, Däßler KU, Behringer DM, Messmann H, Kretzschmar A, Gallmeier E, Forstbauer H, Kunzmann V, Papke J, Büchner-Steudel P, Vehling-Kaiser U, Springfeld C, Vogel A, Ettrich TJ, Schaaf M, Hausen GZ, Götze TO; Arbeitsgemeinschaft Internistische Onkologie (AIO).Int J Cancer. 2021 Mar 15;148(6):1478-1488. doi: 10.1002/ijc.33336. Epub 2020 Oct 23.PMID: 33038277
  9. A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs.
    Schnoeder TM, Perner F, Heidel FH.Mol Cell Oncol. 2021 Jan 30;8(2):1871172. doi: 10.1080/23723556.2020.1871172.PMID: 33855167 Free PMC article.
  10. Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
    Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G, Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G, Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M, Palumbo GA.Cancer. 2021 Apr 1. doi: 10.1002/cncr.33541. Online ahead of print.PMID: 33794557
  11. The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies?
    Heidel FH
    , Platzbecker U.Hemasphere. 2021 Feb 10;5(3):e537. doi: 10.1097/HS9.0000000000000537. eCollection 2021 Mar.PMID: 33604515 Free PMC article. No abstract available.
  12. Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
    Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH, Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A, Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L, Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo M, Palandri F.Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843. Online ahead of print.PMID: 33590502
  13. Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies.
    Ernst P, Heidel FH.Cancers (Basel). 2021 Feb 4;13(4):612. doi: 10.3390/cancers13040612.PMID: 33557090 Free PMC article. Review.
  14. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B, Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M, Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C, Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N, Cavo M, Breccia M, Bonifacio M.Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.PMID: 33414394 Free PMC article. No abstract available.
  15. Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
    Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M, Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH, Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G, Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F, Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A, Palandri F.Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192. Epub 2020 Nov 21.PMID: 33222197

2020

2020

  1. Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature. 2020 Dec;588(7836):157-163. doi: 10.1038/s41586-020-2968-3. Epub 2020 Nov 25.PMID: 33239784

  2. Saliakoura M, Pozzato C, Rossi MS, Heidel FH, Schnöder TM, Baumgartner J, Freigang S, Rimessi A, Pinton P, Felser AD, Nuoffer JM, Spasenija SP, Bubendorf L, Schmid R, Berezowska SA, and Konstantinidou G. PLCgamma1 inhibition mediates the survival of KRAS-mutant lung cancer during hypoxia. Nat Cell Biol. 2020 Oct 19. doi: 10.1038/s41556-020-00592-8.
  3. Brandt S, Ballhause TM, Bernhardt A, Becker A, Salaru D, Le-Deffge HM, Fehr A, Fu Y, Philipsen L, Djudjaj S, Müller AJ, Kramann R, Ibrahim M, Geffers R, Siebel C, Isermann B, Heidel FH, Lindquist JA, Mertens PR. Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression. J Am Soc Nephrol. 2020 Aug 28; ASN.2019121289.
  4. Cortes JE, Heidel FH, Fiedler W, Smith BD, Robak T, Montesinos P, Candoni A, Leber B, Sekeres MA, Pollyea DA, Ferdinand R, Ma WW, O'Brien T, O'Connell A, Chan G, Heuser M. Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. J Hematol Oncol. 2020 Jul 14;13(1):92.
  5. Vu T, Straube J, Porter AH, Bywater M, Song A, Ling V, Cooper L, Pali G, Bruedigam C, Jacquelin S, Green J, Magor G, Perkins A, Chalk AM, Walkley CR, Heidel FH, Mukhopadhyay P, Cloonan N, Gröschel S, Mallm JP, Fröhling S, Scholl C, Lane SW. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nature Commun. 2020 Jun 15;11(1):3021.
  6. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Leukemia. 2020 Jul;34(7):1949-1953.
  7. Midic D, Rinke J, Perner F, Müller V, Hinze A, Pester F, Landschulze J, Ernst J, Gruhn B, Matziolis G, Heidel FH, Hochhaus A, Ernst T. Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. Leukemia. 2020 Aug;34(8):2198-2205. doi: 10.1038/s41375-020-0869-y.
  8. Palandri F, Breccia M, Bonifacio M, Polverelli N, Elli EM, Benevolo G, Tiribelli M, Abruzzese E, Iurlo A, Heidel FH, Bergamaschi M, Tieghi A, Crugnola M, Cavazzini F, Binotto G, Isidori A, Sgherza N, Bosi C, Martino B, Latagliata R, Auteri G, Scaffidi L, Griguolo D, Trawinska M, Cattaneo D, Catani L, Krampera M, Lemoli RM, Cuneo A, Semenzato G, Foà R, Di Raimondo F, Bartoletti D, Cavo M, Palumbo GA, Vianelli N. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer. 2020 Mar 15;126(6):1243-1252. doi: 10.1002/cncr.32664.
  9. Kaiser A, Schmidt M, Huber O, Frietsch JJ, Scholl S, Heidel FH, Hochhaus A, Müller JP, Ernst T. SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. Leukemia. 2020 Mar 25. doi: 10.1038/s41375-020-0803-3
  10. Palandri F, Breccia M, Tiribelli M, Bonifacio M, Benevolo G, Iurlo A, Elli EM, Binotto G, Tieghi A, Polverelli N, Martino B, Abruzzese E, Bergamaschi M, Heidel FH, Cavazzini F, Crugnola M, Bosi C, Isidori A, Auteri G, Forte D, Latagliata R, Griguolo D, Cattaneo D, Trawinska M, Bartoletti D, Krampera M, Semenzato G, Lemoli RM, Cuneo A, Di Raimondo F, Vianelli N, Cavo M, Palumbo GA. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. Hematol Oncol. 2020 Apr 9. doi: 10.1002/hon.2737.
  11. Reich D, Kresinsky A, Müller JP, Bauer R, Kallenbach J, Schnoeder TM, Heidel FH, Fässler R, Mann M, Böhmer FD, Jayavelu AK. SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. Leukemia. 2020 May;34(5):1444-1449. doi: 10.1038/s41375-019-0676-5.
  12. Austin R, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Haque A, Heidel FH, D’Andrea R, Mullally A, Milsom MD, Bywater M, Lane SW. Distinct effects of ruxolitinib vs. interferon-alpha on myeloproliferative neoplasm haematopoietic stem cell populations. Leukemia. 2020 Apr;34(4):1075-1089.

2019

2019

  • Al-Batran S*, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, Kopp H, Mayer F, Haag G, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens U, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer D, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal L, Hartmann J, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu F, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein W, Schuler M, Schmalenberg H, Hofheinz R, on behalf of the Float4-AIO I. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. (Originalartikel)
    LANCET (LONDON, ENGLAND). 2019; 393(10184):1948-1957.
  • Hirt C*, Iannazzo S, Chiroli S, McGarry L, le Coutre P, Stenke L, Dahlén T, Lipton J. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia. (Originalartikel)
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019; 17(4):555-567.
  • Kranz J*, Schlager D, Mühlstädt S, Nagler J, Wagenlehner F, Schneidewind L. [Barriers to guideline adherence : Identification of barriers to guideline adherence using a survey on the AWMF S3 guideline epidemiology, diagnosis, treatment, and management of uncomplicated bacterial, community-acquired urinary tract infections in adult patients]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2019; Jan(8).
  • Michallet M*, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox C, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J, on behalf of the French Cooperative Group for CLL a. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. (Originalartikel)
    BONE MARROW TRANSPLANTATION. 2019.
  • Neumann T*, Schneidewind L, Weigel M, Plis A, Vaizian R, Schmidt A, Krüger W. Ruxolitinib for Therapy of Graft-versus-Host Disease. (Originalartikel)
    BIOMED RESEARCH INTERNATIONAL. 2019; 2019:8163780.
  • Ni M*, Wang L, Yang M, Neuber B, Sellner L, Hückelhoven-Krauss A, Schubert M, Luft T, Hegenbart U, Schönland S, Wuchter P, Chen B, Eckstein V, Krüger W, Yerushalmi R, Beider K, Nagler A, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A. Shaping of CD56 Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis. (Originalartikel)
    FRONTIERS IN IMMUNOLOGY. 2019; 10:547.
  • Samal R*, Sappa P, Gesell Salazar M, Wenzel K, Reinke Y, Völker U, Felix S, Hammer E, Könemann S. Global secretome analysis of resident cardiac progenitor cells from wild type and transgenic heart failure mice: why ambience matters. (Originalartikel)
    JOURNAL OF CELLULAR PHYSIOLOGY. 2019; 234(7):10111-10122.
  • Schnabel M*, Wagenlehner F, Schneidewind L. Perioperative antibiotic prophylaxis for stone therapy. (Originalartikel)
    CURRENT OPINION IN UROLOGY.  (open access) 2019; 29(2):89-95.
  • Schneidewind L*. [Benefits and risks of early versus late ureteric stent removal after kidney transplantation]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2019; Jan(21).
  • Schneidewind L*, Neumann T, Zimmermann K, Weigel M, Schmidt C, Krüger W. Is BK Virus-Associated Cystitis a Generalized Epithelial Disease?. (Originalartikel)
    ACTA HAEMATOLOGICA. 2019; 141(2):65-67.

2018

2018

  • Anheuser P*, Mühlstädt S, Kranz J, Schneidewind L, Steffens J, Fornara P. Significance of Hyperbaric Oxygenation in the Treatment of Fournier's Gangrene: A Comparative Study. (Originalartikel)
    UROLOGIA INTERNATIONALIS. 2018; 101(4):467-471.
  • Boehm K*, Siegel F, Schneidewind L, Kranz J, Spachmann P, Frank T, Huck N, Imkamp F, Pelzer A. Antibiotic Prophylaxis in Prostate Biopsies: Contemporary Practice Patterns in Germany. (Originalartikel)
    FRONTIERS IN SURGERY. 2018; Jan 24(5):2.
  • Buchhold B*, Lutze S, Arnold A, Jülich A, Daeschlein G, Wendler M, Jünger M, Hannich H. Psychosocial distress and desire for support among skin cancer patients - impact of treatment setting. (Originalartikel)
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG.  (open access) 2018; 16(7):861-872.
  • Buchhold B*, Lutze S, Arnold A, Jülich A, Daeschlein G, Wendler M, Jünger M, Hannich H. Psychosoziale Belastung und Unterstützungswunsch von Hauttumorpatienten - Einfluss des Behandlungs-Settings. (Originalartikel)
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2018; 7(16):861-872.
  • Grabarczyk P*, Winkler P, Delin M, Sappa P, Bekeschus S, Hildebrandt P, Przybylski G, Völker U, Hammer E, Schmidt C. The N-terminal CCHC zinc finger motif mediates homodimerization of the transcription factor BCL11B. (Originalartikel)
    MOLECULAR AND CELLULAR BIOLOGY. 2018; 38(5).
  • Kranz J*, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner F. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients: Part 1. (Originalartikel)
    UROLOGIA INTERNATIONALIS. 2018; Jan(17).
  • Kranz J*, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, Helbig S, Vahlensieck W, Naber K, Schmiemann G, Wagenlehner F. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. (Originalartikel)
    UROLOGIA INTERNATIONALIS. 2018; Mar(14).
  • Kranz J*, Schmidt S, Lebert C, Schneidewind L, Schmiemann G, Wagenlehner F. In Reply. (Originalartikel)
    DEUTSCHES ARZTEBLATT INTERNATIONAL. 2018; 115(11):192.
  • Kranz J*, Schmidt S, Schneidewind L. Current Evidence on Nonantibiotic Prevention of Recurrent Urinary Tract Infections. (Originalartikel)
    EUROPEAN UROLOGY FOCUS. 2018.
  • Kranz J*, Schlager D, Anheuser P, Mühlstädt S, Brücher B, Frank T, Barski D, Mayr R, Lunacek A, Macharia-Nimietz E, Steffens J, Grolle J, Pelzer A, Schneidewind L. Desperate need for better management of Fournier's gangrene. (Originalartikel)CENTRAL EUROPEAN JOURNAL OF UROLOGY. 2018; 71(3):360-365.
  • Schneidewind L*, Neumann T, Probst K, Schmidt C, Krüger W. Recovery from hypogonadism and male health in adult allogeneic stem cell transplantation. (Originalartikel)
    EUROPEAN JOURNAL OF HAEMATOLOGY. 2018; Mar(6).
  • Schneidewind L*, Neumann T, Schmidt C, Krüger W. Comparison of intravenous or intravesical cidofovir in the treatment of BK polyomavirus-associated hemorrhagic cystitis following adult allogeneic stem cell transplantation-A systematic review. (Originalartikel)
    TRANSPLANT INFECTIOUS DISEASE : AN OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY. 2018; e12914.
  • Schneidewind L*. [School-based prevention programmes for adolescents: HIV, sexually transmitted infections, and pregnancy]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2018; May(9).
  • Steininger A*, Ebert G, Becker B, Assaf C, Möbs M, Schmidt C, Grabarczyk P, Jensen L, Przybylski G, Port M, Kuß A, Ullmann R. Genome-Wide Analysis of Interchromosomal Interaction Probabilities Reveals Chained Translocations and Overrepresentation of Translocation Breakpoints in Genes in a Cutaneous T-Cell Lymphoma Cell Line. (Originalartikel)
    FRONTIERS IN ONCOLOGY. 2018; 8:183.
  • Stentzel U*, Bahr J, Fredrich D, Piegsa J, Hoffmann W, van den Berg N. Is there an association between spatial accessibility of outpatient care and utilization? Analysis of gynecological und general medical care. (Originalartikel)
    BMC HEALTH SERVICES RESEARCH.  (open access) 2018; 18(1):322.
  • Wang L*, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann J, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen B, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho A, Dreger P, Schmitt M, Schmitt A. Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects. (Originalartikel)
    FRONTIERS IN IMMUNOLOGY. 2018; 9:2207.
  • Heidel F*, Al-Ali H, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T, OSHO S. Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. (Letter)
    LEUKEMIA. 2018; 32(9):2085-2087.

2017

2017

  • Jülich A*, Spreu T, Buchhold B, Usichenko T. The Impact of Integrated Multidisciplinary Palliative Care Program on Symptoms in Patients at the Palliative Care Ward-An Audit and a Protocol of Prospective Controlled Investigation. (Originalartikel)
    JOURNAL OF PALLIATIVE CARE. 2017. (In Press)
  • Barski D*, Gerullis H, Ecke T, Kranz J, Schneidewind L, Leistner N, Queissert F, Mühlstädt S, Grabbert M, Tahbaz R, Pelzer A, Joukhadar R, Klinge U, Boros M, Bader W, Naumann G, Puppe F, Otto T. Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. (Originalartikel)
    INTERNATIONAL JOURNAL OF SURGERY (LONDON, ENGLAND). 2017; 42:27-33.
  • Buchhold B*, Arnold A, Hannich H, Lutze S, Jülich A, Winkler M, Bahlmann J, Eggert C, Jünger M. Stationäre Hauttumorpatienten - Psychosoziale Belastung und Unterstützungswunsch. (Originalartikel)
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2017; 15(8):791-800.
  • Buchhold B*, Arnold A, Lutze S, Jülich A, Winkler M, Bahlmann J, Eggert C, Jünger M, Hannich H. Psychosocial distress and desire for support among inpatients with skin cancer. (Originalartikel)
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG. 2017; 15(8):791-799.
  • Busemann C*, Jülich A, Buchhold B, Schmidt V, Schneidewind L, Pink D, Schmidt C, Neumann T, Krüger W. Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation. (Originalartikel)
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2017.
  • Izykowska K*, Przybylski G, Gand C, Braun F, Grabarczyk P, Kuß A, Olek-Hrab K, Torres A, Vermeer M, Zoutman W, Tensen C, Schmidt C. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome. (Originalartikel)
    ONCOTARGET. 2017; 8(24):39627-39639.
  • Kranz J*, Schmidt S, Lebert C, Schneidewind L, Vahlensieck W, Sester U, Fünfstück R, Helbig S, Hofmann W, Hummers E, Kunze M, Kniehl E, Naber K, Mandraka F, Mündner-Hensen B, Schmiemann G, Wagenlehner F. [Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients : Update 2017 of the interdisciplinary AWMF S3 guideline]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2017; 56(6):746-758.
  • Kranz J*, Schmidt S, Lebert C, Schneidewind L, Schmiemann G, Wagenlehner F. Uncomplicated Bacterial Communityacquired Urinary Tract Infection in Adults. (Originalartikel)
    DEUTSCHES ARZTEBLATT INTERNATIONAL. 2017; 114(50):866-873.
  • Neumann T*, Plis A, Weigel M, Stracke S, Friesecke S, Stecher S, Schneidewind L, Busemann C, Schmidt C, Krüger W. No Relapse of Calcineurin Inhibitor-Associated Thrombotic Microangiopathy after Discontinuation of Eculizumab. (Originalartikel)
    ACTA HAEMATOLOGICA. 2017; 138(4):194-197.
  • Neumann T*, Schneidewind L, Thiele T, Pink D, Schulze M, Schmidt C, Krüger W. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation. (Originalartikel)
    TRANSPLANT INFECTIOUS DISEASE : AN OFFICIAL JOURNAL OF THE TRANSPLANTATION SOCIETY. 2017.
  • Reuß D*, Altenbuchner J*, Mäder U*, Rath H, Ischebeck T, Sappa P, Thürmer A, Guerin C, Nicolas P, Steil L, Zhu B, Feussner I, Klumpp S, Daniel R, Commichau F, Völker U, Stülke J. Large-scale reduction of the Bacillus subtilis genome: Consequences for the transcriptional network, resource allocation, and metabolism. (Originalartikel)
    GENOME RESEARCH. 2017; 27(2):289-299.
  • Schneidewind L*, Neumann T, Knoll F, Zimmermann K, Smola S, Schmidt C, Krüger W. Are the Polyomaviruses BK and JC Associated with Opportunistic Infections, Graft-versus-Host Disease, or Worse Outcomes in Adult Patients Receiving Their First Allogeneic Stem Cell Transplantation with Low-Dose Alemtuzumab?. (Originalartikel)
    ACTA HAEMATOLOGICA. 2017; 138(1):3-9.
  • Schneidewind L*, Kranz J, Schlager D, Barski D, Mühlsteadt S, Grabbert M, Queissert F, Frank T, Pelzer A. Mulitcenter study on antibiotic prophylaxis, infectious complications and risk assessment in TUR-P. (Originalartikel)
    CENTRAL EUROPEAN JOURNAL OF UROLOGY. 2017; 70(1):112-117.
  • Schneidewind L*, Neumann T, Kranz J, Knoll F, Pelzer A, Schmidt C, Krüger W. Nationwide survey of BK polyomavirus associated hemorrhagic cystitis in adult allogeneic stem cell transplantation among haematologists and urologists. (Originalartikel)
    ANNALS OF HEMATOLOGY. 2017; 96(5):797-803.
  • Schneidewind L*, Kranz J, Schlager D, Pelzer A. [Nationwide survey among institutes of microbiology in academic medicine : Is the interdisciplinary approach the right way to treat patients with urogenital infections?]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2017; 56(6):779-784.
  • Schneidewind L*. [Antibiotic prophylaxis for transrectal prostate biopsy]. (Originalartikel)
    DER UROLOGE. AUSG. A. 2017; 56(1):60-64.
  • Schneidewind L*, Neumann T, Zimmermann K, Schmidt C, Krüger W. Urological complications associated with adult allogeneic stem cell transplantation. (Letter)
    AMERICAN JOURNAL OF HEMATOLOGY. 2017.